« Return to News | Awards & Advancement

Endocyte appoints Novartis vet David Meek as chief commercial officer

Monday, July 30, 2012 03:49 PM

Endocyte, an Indianapolis, Ind.-based biopharmaceutical company focused on cancer and inflammatory diseases, has appointed David Meek to the newly created position of chief commercial officer. He will be responsible for the development of Endocyte’s commercial team and overall commercial strategy and execution.

Meek brings more than 20 years of pharmaceutical industry experience, including general management in North America and Europe, and numerous successful launches for oncology and specialty products. He comes to Endocyte after more than seven years at Novartis Pharma, where he was most recently the head of Northern and Central Europe oncology and launched key new oncology products and indications for Novartis. Previously, Meek served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products. Prior to his roles at Novartis, Meek served at Johnson & Johnson for 15 years, where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.